Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: J Diet Suppl. 2011 Mar;8(1):19–33. doi: 10.3109/19390211.2010.542233

Table 3.

Dendritic cell viability following treatment with BRC extracts.

A. Relative percent viability compared to the DMSO control
Relative Extract Concentrationa BRC-301 DC2.4 BRC-304 DC2.4 BRC-306 DC2.4 BRC-301 bmDCs
Low 100 ±2 92 ±10 98 ±1 107 ±3
Medium 99 ±2 85 ±2* 94 ±1 116 ±5*
High 101 ±3 96 ±2 100 ±1 107 ±8
B. Relative percent viability compared to the LPS/DMSO control
Relative Extract Concentrationa BRC-301 DC2.4 BRC-304 DC2.4 BRC-306 DC2.4 BRC-301 bmDCs
Low 94 ±4 100 ±4 99 ±4 91 ±4
Medium 97 ±5 102 ±3 92 ±2 97 ±1
High 101 ±7 95 ±3 95 ±5 92 ±5

DC2.4 and bmDCs were cultured (n=3) in 6-well plates (1×106 per well) with DMSO, LPS (+DMSO), and/or varying concentrations of extracts for 48 hours. Viability of extract-treated cells was calculated as percent of either the DMSO-treated (A) or LPS/DMSO-treated (B) controls plus SEM. Data are representative of three experiments (n=4-6).

a

Extract concentrations varied among extracts as follows: for all extracts tested, the low and medium concentrations tested were 0.5 and 5.0 μg/ml, respectively. For BRC-301 and BRC-306, the high concentration tested was 25 μg/ml while 10 μg/ml was the highest concentration tested for BRC-304 due to decreased viability at higher concentrations.

*

indicates p < .05